Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are...
MPN (Myeloproliferative Neoplasms)The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis,...
HepatomegalyMyelofibrosis Transformation in Essential Thrombocythemia4 moreThis phase II trial studies how well nivolumab works in treating patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia MyelofibrosisA lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib.
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia...
Polycythemia VeraEssential ThrombocythemiaThis open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)
ThrombocytosisIron-Deficiency AnemiaThe aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.
A Safety Study of XL019 in Adults With Myelofibrosis
Myeloproliferative DisordersMyelofibrosis3 moreThe purpose of this study is to evaluate the safety and tolerability of XL019 in adults with myelofibrosis. XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. JAK2 is activated by cytokine and growth factor receptors and phosphorylates members of the STAT family of inducible transcription factors. Activation of the JAK/STAT pathway promotes cell growth and survival, and is a common feature of human tumors. JAK2 is activated by mutation in the majority of patients with myelofibrosis, polycythemia vera and essential thrombocytosis and appears to drive the inappropriate growth of blood cells in these conditions.
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera Myelofibrosis1 morePhase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line...
Essential ThrombocythemiaProspective national multicenter randomized open label phase IIb RUXBETA trial.
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia...
Primary MyelofibrosisPost-polycythemia Vera Myelofibrosis1 morePhase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV MF)1 moreThis is a multicenter, Phase 1b study with dose escalation and expansion cohorts designed to assess the safety, tolerability, PK, and preliminary efficacy of PU-H71 in subjects with PMF, Post-PV MF, Post-ET MF, taking stable doses of ruxolitinib.